The factors affecting maturation of human antibody responses to PS antigens are poorly understood (1, 2) . However, it is clear that the immunogenicity of a PS in infants can be greatly increased by covalently coupling the PS to a protein carrier (2, 3) . In the resulting PS-protein conjugate, thymic-dependent features are conferred to the PS (4), and one observes boostable increases in serum antibody upon reinjection of the conjugate (4-7).
In recent years, the conjugate vaccine approach to immunization of infants with PS antigens has been applied most extensively to the development of a vaccine against Haemophilus influenzae type b (Hib) disease (3) . This organism is the most common cause of bacterial meningitis in children in the United States. Several investigational Haemophilus type b conjugate vaccines have been prepared and tested in subjects of different ages (5) (6) (7) (8) . These conjugates are immunogenic in infants less than 12 months of age, a group characterized by very poor antibody responses to conventional Hib PS vaccine. Thus, detailed studies of the immune responses of humans of different ages to immunization with these unique conjugated antigens provide an opportunity to understand better the ontogeny of immune responses to PS antigens, especially in relation to the possible effects of the age of the host or the manner of presentation of the PS (i.e. T independent versus T dependent).
Several previous studies have examined the serum isotype responses of subjects immunized with different forms of Hib PS (5, 8-1 1). Children and adults immunized for the first time with either conventional Hib PS vaccine or one of the new Hib conjugate vaccines show both IgM and IgG responses. In addition, children primed in infancy with Hib PS-outer membrane protein conjugate vaccine and boosted 10-1 5 months later with either conventional Hib PS vaccine or with conjugate vaccine show evidence of a memory antibody response to the booster injection, and have substantial increases in IgG anti-Hib PS antibody (12) . A similar memory antibody response to reimmunization recently was reported in children primed in infancy with an Hib oligosaccharide-protein conjugate vaccine (13) . 18 1 In humans and experimental animals, specific antibodies are not distributed randomly among the IgG subclasses (14) . For example, in humans, IgG antibody responses to protein antigens are predominantly IgGl (15, 16) whereas IgG antibodies to polysaccharides such as streptococcal group A carbohydrate (1 7), dextran (1 8), or several pneumococcal capsular polysaccharides (19, 20) are predominantly IgG2. Until recently, the IgG responses to Hib PS were thought to be predominantly IgG2 (2 1). Further, the poor antibody responses of infants immunized with conventional Hib PS vaccine were thought, possibly to relate to delayed maturation of the ability of infants to produce antibodies of the IgG2 subclass. We recently found that immunization of adults with conventional Hib PS vaccine or Hib PS-diphtheria toxoid conjugate vaccine elicits substantial quantities of both IgGl and IgG2 antibodies (22) . These results have been confirmed in a study by Makela et al. (23) in Finland. However, no comparable data are available on the subclass composition of IgG anti-Hib PS antibody in sera from immunized children. Such information is needed to understand better the immune mechanisms that infants and children are capable of mounting for protection against Hib disease.
The purposes of the present study were 2-fold: first, to compare the IgGl and IgG2 subclass composition of serum anti-Hib PS antibody evoked by immunization of children with either conventional I-Iib PS vaccine, or with Hib PS coupled to a partially purified outer membrane protein of Neisseria meningitidis (Hib PS-OMP conjugate vaccine); and, second, to determine the subclass composition of IgG antibody elicited by a booster injection with either conventional Hib PS vaccine or Hib PS-OMP conjugate vaccine in children previously primed in infancy with conjugate vaccine.
METHODS
Subject selection. A total of 117 healthy children was vaccinated with conventional Hib PS vaccine or a conjugate of Hib PS coupled to a partially purified N. meningitidis OMP (24) . Informed consent was obtained from one or both parents of the children. The protocol was approved by the Human Studies Committee of Washington University School of Medicine.
Group 1 consisted of 51 healthy white children who were vaccinated with Hib PS vaccine for the first time. The children ranged in age from 24 to 83 months (mean + SD = 47 f 17). A total of 38 children were vaccinated with 5 pg intramuscularly of vaccine prepared by P. Anderson, University of Rochester, Rochester, NY, a dose within the maximally immunogenic range (25, 26) . The remaining 13 children received 25 pg subcutaneously of Hib PS vaccine prepared by Praxis Biologics (Rochester, NY). There were no significant qualitative or quantitative differences in antibody responses of the children to the two vaccines and, therefore, the data from both groups were combined.
Group 2 consisted of 28 infants who were vaccinated for the first time with Hib PS-OMP conjugate vaccine. A single lot of vaccine was used (lot 1003/C-L680, Merck Sharp & Dohme Research Laboratories, West Point, PA). Each dose, administered intramuscularly, contained 7 pg of polysaccharide and 43 pg of OMP. The 28 children in group 2 ranged in age from 2 to 17 months (mean f SD = 7.8 f 4.9). Twenty-seven were white and one was black. They were selected based upon availability of sufficient sera for testing from 63 vaccinated subjects described in a previous report (7) . Blood samples were obtained by venipuncture prior to immunization and 1-2 months after vaccination. Pre-and postimmunization samples were assayed for total anti-Hib PS antibody concentration by a RABA (25) . Postimmunization sera were assayed for IgG, IgG1, and IgG2 anti-Hib PS antibody to ELISA as described below.
Serology. Serum IgG and IgGl anti-Hib PS antibody concentrations were measured by ELISA as described (22, 25) . In brief, Hib PS coupled to poly-1-lysine served as the antigen on the plate. Wells in a microtiter dish were incubated sequentially with test sera, biotin-conjugated secondary antibody specific for IgG or IgGl, avidin coupled to alkaline phosphatase, and p-nitrophenyl phosphate. Absorbance was monitored with a Titertek Multiscan spectrophotometer (Flow Laboratories, McLean, VA). Murine monoclonal antibody (HG11) specific for human IgGl was used as the secondary antibody in the IgGl subclass assay. The specificity of this reagent has been described (27) . The reagent used to detect IgG consisted of biotinylated heavy chainspecific goat antibody to human IgG purchased from Tago (Burlingame, CA). Serum IgG2 anti-Hib PS antibody was measured by ELISA as described (22, 25) except that a murine monoclonal antibody (HP 6014, ICN Immunology, Lisle, IL) was used rather than a polyclonal monkey antiserum. Inasmuch as the monoclonal was available as ascitic fluid, we used a biotinconjugated goat anti-mouse IgG (Tago) to detect binding of the monoclonal antibody. This goat antiserum had been absorbed to remove reactivity with human IgG.
Each class or subclass ELISA included known positive and negative control sera as well as serial 2-fold dilutions of the U.S. Office of Biologics (Bethesda, MD) H. influenzae type b human serum reference pool. A complete titration curve was generated for each test serum and the reference serum. The isotype specific antibody concentrations (pg/ml) of the test serum were assigned by comparison of the dilutions of test serum that produced an absorbance value of 0.6 with that of the U.S. Office of Biologics standard serum pool as described (22) . In replicate assays performed on different days, the average difference in the respective IgG, IgG1, and IgG2 anti-Hib PS concentrations in individual test sera ranged from 12 to 18% (22) .
Statistics. Analysis of antibody responses was performed on logarithmically transformed data. A Student's t test (two-tailed) was used to compare the geometric mean concentrations of serum antibody among the groups. This method also was used to compare the geometric mean of the IgGI/IgG2 anti-Hib PS antibody ratios among the groups of subjects. Table 1 summarizes the anti-Hib PS antibody responses of the infants and older children immunized for the first time with Hib PS-protein conjugate vaccine or conventional Hib PS vaccine, respectively. The total antibody data shown are from the radioantigen binding assay which measures all classes of immunoglobulin. As expected, before immunization, the children in group 1 who ranged in age from 24 to 83 months of age had higher serum antibody concentrations than the infants in group 2 who were 2 to 17 months of age (0.94 versus 0.17 pg/ml, p < 0.001). After vaccination, subjects in both groups showed increases of approximately 10-fold or more in the respective geometric means of the total antibody concentrations ( p < 0.001 for each group, comparing the respective geometric means of the values in pre-and postimmunization sera for each group). However, the geometric mean of the total antibody concentrations in the older children given conventional Hib PS vaccine was higher than that of the Figure 1 shows the individual ratios of IgGl to IgG2 antibody in postimmunization sera from individual subjects immunized for the first time with Hib PS vaccine or Hib PS-OMP conjugate vaccine. In contrast to the data in Table 1 , which include the results from all subjects in the appropriate groups, the data in Figure 1 are limited to the subjects considered to be IgG "responders" to vaccination. Responders were defined as those who had 2-fold or more increase in antibody after vaccination, and r 1.9 pg/ml of IgG antibody in postimmunization sera. Individuals who did not meet this definition were excluded because of the high error in determining the ratios of subclass-specific antibody concentrations present in low titer sera. Twenty-six of the 51 children (51%) vaccinated with conventional Hib PS vaccine, and 12 of the 28 infants (43%) who received conjugate vaccine were considered to be IgG responders. The mean + SD of the ages of the responders given PS vaccine was 51 + 17 compared with 43 f 16 in the nonresponders ( p < 0.05, onetail); the corresponding values for the group given conjugate vaccine was 9.8 + 4.8 and 6.2 + 4.7 months, respectively ( p < 0.05, one-tail). There were no significant differences in the respective geometric means of the preimmunization total antibody concentrations of nonresponders and responders given conventional Hib PS vaccine or conjugate vaccine (data not shown) (IgG and IgG subclass determinations were not routinely performed in preimmune sera because of the low level of antibody present). As shown in Figure 1 , the IgG antibody responses of most subjects immunized with PS vaccine were predominantly IgG1 (IgG 1/IgG2 >I), although five of the 26 responder children (19%) had predominantly IgG2 responses (IgGlIIgG2 <I). In contrast, all 12 IgG responders given conjugate vaccine had predominantly or exclusively IgGl responses. The geometric mean ratio of IgGl to IgG2 in the responders given conventional Hib PS vaccine was 2.8 compared with 14.9 in the responders given conjilgate vaccine ( p < 0.001). Table 2 summarizes the respective antibody responses to booster immunization with conventional Hib PS vaccine or Hib PS-OMP conjugate vaccine in children previously primed with conjugate vaccine. This analysis includes data from all subjects who received a booster injection, irrespective of their responder/ nonresponder status (see below). The children were boosted at 1 0 0 0 . 0~ The bars represent the geometric means of the ratios for each group.
RESULTS

P S V A C C I N E PS-OMP C O N J U G A T E S U B J E C T S I M M U N I Z E D F O R T H E F I R S T T I M E
14 to 3 1 months of age, which was 10 to 15 months after their last injection with conjugate vaccine (12) . The mean age of the group boosted with Hib PS vaccine was 19.9 months and that of the group boosted with conjugate vaccine was 18.8 months ( p > 0.5). There were no significant differences in the respective geometric means of the total, IgG, IgG1, and IgG2 Hib PS antibody concentrations in the sera from the two groups. Both groups showed predominantly IgGl responses although in the postimmune sera there also were substantial concentrations of IgG2 antibody evoked by the booster injections. Figure 2 shows the ratios of IgGl to IgG2 antibody of the individual subjects given booster immunizations. As was the case SUBCLASS DISTRIBUTION OF ANTIBODIES TO HIB 183 with the data presented in Figure 1 , the data shown in Figure 2 represent the individual ratios of the "responders" only. However, in the latter instance, 26 of the 28 subjects boosted with conventional Hib PS vaccine (93%) and all 10 subjects boosted with conjugate vaccine were considered IgG responders. A total of 22 of the 26 responders boosted with conventional Hib PS vaccine and seven of the 10 children boosted with conjugate vaccine showed predominantly IgG 1 responses (ratios > 1.0).
There was no significant difference in the geometric means of the IgGl to IgG2 antibody ratios of the children in the two groups of (2.6 versus 4.2, p = 0.29). The geometric means of the ratios also did not differ significantly from the geometric mean IgG I /IgG2 ratio of the children 24 to 83 months of age in group 1 given conventional Hib PS vaccine for the first time (geometric mean = 2.8).
DISCUSSION
Recent reports indicate that the IgG antibody responses to some PS antigens are not restricted to IgG2, and that most adults vaccinated with Hib or meningococcal group A PS develop substantial amounts of IgGl as well as IgG2 antibody (22, 23, 28, 29) . Our results extend the data on anti-Hib PS IgG subclass responses to measurement of the IgGl and IgG2 responses of children and infants vaccinated with conventional Hib PS vaccine or a Hib-PS protein conjugate vaccine containing an outer membrane protein as the carrier. Because of previous data on the lack of immunogenicity of the Hib PS vaccine in infants (2, 3), we only immunized the infants in this study with conjugate vaccine. The data indicate that infants < 18 months of age given conjugate vaccine show IgG responses that are highly restricted to IgGl (Fig. 1) . In contrast, children 24 to 83 months of age immunized with conventional Hib PS vaccine have both IgGl and IgG2 antibody responses with a predominance of IgGl (IgG 1 /IgG% > 1, Fig. 1 ). The restricted IgG 1 antibody responses of the infants given the conjugate vaccine are similar to those observed previously in patients 24 to 59 months of age recovering from invasive Hib disease (30) . Further investigation will be required to determine the potential importance of the differences in IgG subclass distribution of anticapsular antibody in protection against disease (3 1).
It is not clear why the infants in this study immunized for the first time with conjugate vaccine produced predominantly or exclusively IgGl responses. One possible explanation is that IgGl may be the predominant subclass induced by immunization with T-dependent antigens, whereas T-independent antigens may evoke predominantly IgG2 responses (23) . Consistent with this explanation is our recent finding of a predominance of IgGl antibody responses in sera from 17 children, 24-60 months of age, vaccinated for the first time with Hib PS-OMP conjugate vaccine (geometric mean IgGl and IgG2 antibody concentrations of 4.47 and 0.72 pg/ml; sera kindly provided by Dr. Phillip Vella, Merck, Sharp & Dohme). The hypothesis that T-dependent antigens evoke higher IgGl responses than T-independent forms of the antigen does not explain previous data indicating that adults given conventional Hib PS vaccine (T independent) or Hib PS-diphtheria toxoid conjugate vaccine (presumably, T dependent) show relatively similar proportions of IgGl and IgG2 anti-Hib PS antibody (22, 23) . In addition, six adults immunized previously with the same Hib PS-OMP conjugate vaccine as used in the infants in the present study showed substantial increases in both IgG 1 and IgG2 antibody (geometric mean ratio of IgG 1 to IgG2 in postimmunization sera of 1.1, data not shown). It is likely that most of the adults vaccinated in these studies had been exposed previously to type b Haemophilus or to enteric bacteria containing polysaccharide antigens cross-reactive with the type b polysaccharide. In contrast, the majority of the immunized infants and older children may not have been exposed previously (or, if previously exposed, not to a form of the antigen suitable for priming in this age group). Conceivably, in unprimed individuals, the conjugate vaccine primarily evokes IgGl re-sponses, whereas primed individuals show both IgGl and IgG2 responses. Whether the predominance of IgGl responses of the infants and older children to the primary immunization with the conjugate reflects lack of activation of B cell subsets specific for IgG2 or lack of isotype switching to IgG2 by the activated B cells cannot be distinguished by the present data (14, 32) .
Not all infants <18 months of age vaccinated with conjugate vaccine develop serum antibody levels > 1 pg/ml (5-7). However, previous studies have shown that children primed in infancy with conjugate vaccine have IgG memory antibody responses to a subsequent booster injection with either conventional Hib PS vaccine (12, 13) or conjugate vaccine (12) , and this memorytype response is observed even in children who show meager antibody responses to the primary immunization. The magnitude of the total IgG responses of the primed children to reimmunization with the polysaccharide vaccine is comparable to that of adults immunized for the first time with conventional Hib PS vaccine (12, 13) . Our study provides data on the IgG subclass composition of the booster responses of children primed in infancy with the Hib PS-OMP conjugate vaccine. As summarized in Table 2 and Figure 2 , most subjects boosted with either conventional Hib PS vaccine or conjugate vaccine showed a predominance of IgGl antibody (IgGl/IgG2 >1.0). This result is consistent with increased expression of B cell clones previously stimulated by the primary immunization with the conjugate. However, after the booster immunization, nearly all of the subjects also showed substantial increases in their serum concentrations of IgG2 antibody, and seven of the 36 subjects showed a predominance of IgG2 antibody to the booster injection (IgG 1 to IgG2 ratio < 1, Fig. 2 ). Note that the geometric mean IgG2 antibody concentration after the booster injection with the PS vaccine is substantially higher than that observed in children, 24-to 83 months of age, immunized for the first time with conventional Hib PS vaccine (4.8 versus 0.77 pg/ml, p < 0.001; compare Table 2 to Table I) .
Similarly, the IgGl responses to the booster injection with Hib polysaccharide vaccine are higher than primary vaccination with polysaccharide, even when given at an older age (geometric means of 12.7 versus 2.24 pg/ml, p < 0.001). Therefore, although primary immunization of infants with conjugate vaccine evokes a restricted IgGl antibody response, it primes for both IgGl and IgG2 booster responses to a subsequent injection with conventional Hib PS vaccine or Hib PS-OMP conjugate vaccine (Table  2) . Although not examined directly, the IgG2 responses of the children to the booster injection could result from stimulation of new B cell clones or activation of a subclass switch from IgGl to IgG2. To date, the only available data addressing this question are those of Insel and Anderson (32) . They analyzed the clonal diversity of IgG antibody induced by immunization of infants with an Hib oligosaccharide-protein conjugate vaccine, followed by boosting with Hib PS vaccine. In most subjects, reimmunization with the Hib PS vaccine increased expression of clones previously stimulated by the conjugate. However, occasionally new clonotypes were observed (32).
As noted above, the IgG anticapsular antibody response of adults immunized with Hib PS vaccine or Hib PS-protein conjugate vaccines is heterogeneous and is composed mainly of IgGl and IgG2 (22, 23) . Makela et al. (23) recently reported that a few immunized adults also showed a small IgG3 component (~6 % of IgG) and, rarely, an IgG4 component (<I% of IgG). Comparable data are not available from children. It is possible, therefore, that immunized children may also occasionally respond with IgG3 or IgG4 antibody. Attempts are currently underway in our laboratory to develop a quantitative IgG3 and IgG4 anti-Hib PS ELISA to examine this question.
